ABBV logo

AbbVie Inc. (ABBV)

$292.82

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ABBV

Market cap

$517.59B

EPS

3.54

P/E ratio

78.1

Price to sales

7.59

Dividend yield

2.486%

Beta

0.201107

Price on ABBV

Previous close

$294.55

Today's open

$291.50

Day's range

$291 - $294.06

52 week range

$190.75 - $302.93

Profile about ABBV

CEO

ROBERT A. MICHAEL

Employees

57000

Headquarters

North Chicago, IL

Exchange

New York Stock Exchange

Shares outstanding

1.77B

Issue type

Common Stock

ABBV industries and sectors

Healthcare

Pharmaceuticals

News on ABBV

Invest $100,000 in These 4 Dividend Stocks and Collect Passive Income for Life

Four blue-chip dividend payers, including one that sends checks monthly, offer a way to keep the shares and still get paid.

news source

24/7 Wall Street • 2 hours ago

news preview

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

news source

Zacks Investment Research • Nov 17, 2026

news preview

How Did AbbVie's Neuroscience Franchise Perform in Q3?

ABBV's neuroscience franchise delivers 19.5% operational sales growth in Q3, prompting the company to raise its 2026 segment sales outlook to $13 billion.

news source

Zacks Investment Research • 21 hours ago

news preview

Forget SCHD: 4 Dividend Stocks Retirees Should Own Instead

The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) grounds countless retirement portfolios. SCHD screens for durable dividend payers, holds $112.3 billion in net assets and pays a trailing yield near 2.94%.

news source

24/7 Wall Street • Nov 17, 2026

news preview

Invest $200,000 in These 5 Dividend Stocks to Fund Your Retirement Income

Retirement changes the job a portfolio has to do. Once the paychecks stop, every bill depends on what the portfolio produces, and selling shares in a down market to cover expenses locks in losses.

news source

24/7 Wall Street • a day ago

news preview

Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?

Pfizer offers one of the highest yields in healthcare. AbbVie is a Dividend King with solid growth prospects.

news source

The Motley Fool • Nov 14, 2026

news preview

How Did AbbVie's Immunology Franchise Fare in Q3?

ABBV's immunology sales rose 16.6% in Q3, driven by Skyrizi and Rinvoq growth, prompting higher 2026 sales forecasts despite Humira's decline.

news source

Zacks Investment Research • Nov 12, 2026

news preview

3 Pharmaceutical Stocks That Offer Safety and Growth

Market volatility is unpleasant, but it's important that investors don't force themselves into a false choice between safety and growth. Over the last two years, technology stocks, particularly AI stocks, have driven strong portfolio gains for active and passive investors.

news source

MarketBeat • Nov 12, 2026

news preview

ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell?

AbbVie's strong immunology and neuroscience growth offset Humira erosion and persistent aesthetics and oncology challenges.

news source

Zacks Investment Research • Nov 11, 2026

news preview

Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications

– HARMONY IN DIVERSITY is the first study of combined neurotoxin and filler treatment in adults on glucagon-like peptide-1 (GLP-1) medications. In this Phase 4 cohort, participants reported statistically significant improvements in satisfaction with facial appearance and skin quality following a treatment regimen that also included skincare – Interim results from HALO, a Phase 4 study of hyaluronic acid (HA) injectables in adults on GLP-1 medications, showed high patient satisfaction, with 95.7% of participants satisfied or very satisfied that they still looked like themselves – The findings are part of a broad Allergan Aesthetics scientific program at ASDS 2026, advancing research across medical weight loss, multimodal treatment, neurotoxin innovation and skin quality IRVINE, Calif.

news source

PRNewsWire • Nov 8, 2026

news preview

¹ Disclosures

Get started with M1

Invest in AbbVie Inc.

Open an M1 investment account to buy and sell AbbVie Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ABBV on M1